CMV ICP22 Antibody (6F12): sc-56974
- CMV ICP22 Antibody (6F12) is a mouse monoclonal IgG1 CMV ICP22 antibody, cited in 1 publications, provided at 100 µg/ml
- raised against CMV
- recommended for detection of ICP22 Delayed Early Protein of CMV origin by WB and IF
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CMV ICP22 Antibody (6F12). This work is in progress.
CMV ICP22 Antibody (6F12) is a mouse monoclonal IgG1 antibody that detects the CMV ICP22 protein of CMV origin by western blotting (WB) and immunofluorescence (IF). Anti-CMV ICP22 antibody (6F12) is available as the non-conjugated format. Cytomegalovirus (CMV), a member of the herpes virus family, includes other well-known viruses such as herpes simplex virus types 1 and 2, Varicella Zoster Virus, and Epstein Barr virus. These viruses can remain dormant in the body for extended periods, posing risks to immunocompromised individuals. In humans, CMV is referred to as HCMV or human herpesvirus 5 (HHV-5), which typically causes mild symptoms in healthy adults but can lead to severe complications in those with weakened immune systems. CMV ICP22 protein, also known as HWLF1, is a delayed early nuclear viral protein that is secreted from infected cells as a soluble protein. The gene encoding CMV ICP22 is located in the S component of the CMV genome, and CMV ICP22′s function is critical as CMV ICP22 represses both viral and cellular promoters and enhancers, thereby playing a significant role in the regulation of viral gene expression. Understanding CMV ICP22′s function is essential for developing therapeutic strategies against CMV infections, particularly in immunocompromised patients.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CMV ICP22 Antibody (6F12) References:
- Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. | Borchers, AT., et al. 1999. Transpl Immunol. 7: 75-82. PMID: 10544437
- Cytomegalovirus infection in normal and immunocompromised humans. A review. | Drago, F., et al. 2000. Dermatology. 200: 189-95. PMID: 10828625
- The products of human cytomegalovirus genes UL23, UL24, UL43 and US22 are tegument components. | Adair, R., et al. 2002. J Gen Virol. 83: 1315-1324. PMID: 12029146
- Diagnosis of cutaneous cytomegalovirus infection: a review and report of a case. | Toome, BK., et al. 1991. J Am Acad Dermatol. 24: 860-7. PMID: 1646834
- Developmental regulation of human cytomegalovirus receptors in cytotrophoblasts correlates with distinct replication sites in the placenta. | Maidji, E., et al. 2007. J Virol. 81: 4701-12. PMID: 17314173
- Analysis of HSV-I ICP22 effects on HCMV major immediate-early promoter structure. | Luo, J., et al. 2007. Sci China C Life Sci. 50: 292-7. PMID: 17609884
- Impact of cytomegalovirus infection on organ transplant recipients. | Rubin, RH. 1990. Rev Infect Dis. 12 Suppl 7: S754-66. PMID: 2173105
- Human cytomegalovirus ICP22, the product of the HWLF1 reading frame, is an early nuclear protein that is released from cells. | Mocarski, ES., et al. 1988. J Gen Virol. 69 (Pt 10): 2613-21. PMID: 2844970
- Cytomegalovirus infection following liver transplantation: review of the literature. | Kanj, SS., et al. 1996. Clin Infect Dis. 22: 537-49. PMID: 8852975
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CMV ICP22 Antibody (6F12) | sc-56974 | 100 µg/ml | $322.00 |